Pre-, peri- or postmenopausal women of 18 years or above;
Indication for endocrine therapy and already started with tamoxifen, aromatase inhibitors or luteinizing hormone-releasing hormone analogues for at least 4 weeks and planning to continue for the duration of the study;
Experiencing hot flashes with a minimum of 14 per week for at least 1 month and desire to start a pharmacologic intervention.
You may not be if
Pregnant;
Breast feeding;
Patients who receive chemotherapy or immunotherapy/HER2 antibodies within the prior 8 weeks, and patients scheduled for chemotherapy during the study period;
Palliative setting;
Use of venlafaxine or any other antidepressants, also including St. John's wort within the previous year;
Creatinine clearance \< 30 ml/min;
Liver cirrhosis;
Use of gabapentin and/or calcium channel antagonists within 2 weeks of study entry;
Use of oxybutynin before study entry;
Use of any other substances or therapies for the treatment of hot flashes, for instance acupuncture.
Clareo Health | REDucing Hot FLASHes in Women Using Endocrine Therapy.
